96MechEngAmite

It’s supposed to be an amazing vaccine in both efficacy and protection as well as in handling. In addition, it can be easily modified for variants. Trump awarded them $1.7B through OWS. It’s also the same type of vaccine currently used for the flu.

The issue is that they have had major delays in manufacturing as they tried a global rollout using over 10 plants across the world. The US locked up supply for materials due to the Defense Production Act which restricted NVAX’s ability to secure certain critical supplies. The Serum of India is expected to provide 1.1B doses in 22 and recently started a pediatric trial in India for those between 2 and 12.

Expecting to file with the FDA by the end of September. I was a long term holder of the stock…..which has been amazing. 18 months ago the stock was under $10…..it hit $330 in February, then fell back to the $120s and has now recovered to $200. Once they get approval, it could go above 400.